Fig. 4From: Targeting histone methyltransferases and demethylases in clinical trials for cancer therapy a Schematic view of LSD1 principal domains. b Structures of the unselective LSD1/MAO inhibitor tranylcypromine (TCP), the selective LSD1 inhibitors from Oryzon and GSK and the dual HDAC/LSD1 inhibitor 4SC-202Back to article page